Spinal Muscular Atrophy Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers Global Spinal Muscular Atrophy (SMA) Market Analysis and is segmented by Type (Type I, Type II, Type III, and Type IV), Procedure (Gene Replacement Therapy and Drug Therapy), Route of Administration (Oral and Intrathecal), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Spinal Muscular Atrophy Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Spinal Muscular Atrophy Treatment Market Size

Spinal Muscular Atrophy Treatment Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
CAGR 14.50 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Spinal Muscular Atrophy Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Spinal Muscular Atrophy Treatment Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Spinal Muscular Atrophy Treatment Market Analysis

The Global Spinal Muscular Atrophy Treatment Market is expected to register a CAGR of 14.5% during the forecast period.

Due to strict lockdown measures and restricted movement of people, the COVID-19 virus outbreak has had a significant impact on the spinal muscular atrophy medicine industry. The unprecedented coronavirus outbreak (SARS-CoV-2) has cast a shadow over the SMA treatment industry. For instance, according to the article published in the National Institute of Health in May 2020, titled "Spinal muscular atrophy care in the COVID19 pandemic era," the delay in the SMA treatment during the pandemic affected the delivery of clinical care to patients with spinal muscular atrophy (SMA). Moreover, the amount of money available for the R&D and drug development for SMA has been decreasing, as the majority of the money has been spent on COVID-19 vaccine production.

The major factors accounting for the growth of the spinal muscular atrophy treatment market are growing awareness regarding SMA, its diagnosis and treatment, rise in the government initiatives to improve healthcare infrastructure, and increasing R&D activities to develop novel treatment regimens. For instance, in August 2020, the US Food and Drug Administration approved Evrysdi (risdiplam) to treat patients two months of age and older with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement. This is the second drug and the first oral drug approved to treat this disease. Emerging treatment therapies in the treatment of SMA are driving the growth of the market during the forecast period.

However, the high cost of treatment and lack of skilled professionals for surgical procedures and physiotherapy regimens hampers the market to some extent.

Spinal Muscular Atrophy Treatment Industry Overview

The spinal muscular atrophy treatment market is moderately competitive and consists of several major players. With the increasing consolidations of various organizations and product recalls in the healthcare sector, it is expected to generate competitive rivalry among the key players in the future. Some of the major players of the market are Novartis AG, Biogen Inc., F. Hoffmann - La Roche Ltd, and Cytokinetics Inc.

Spinal Muscular Atrophy Treatment Market Leaders

  1. Biogen

  2. F. Hoffmann - La Roche Ltd

  3. Cytokinetics, Inc.,

  4. Novartis AG

  5. Catalyst Pharmaceutical

  6. *Disclaimer: Major Players sorted in no particular order
Spinal Muscular Atrophy Treatment Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Spinal Muscular Atrophy Treatment Market News

  • In August 2021, Novartis announced the lift of a partial clinical trial hold and planned to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with spinal muscular atrophy.
  • In July 2021, Roche launched prescription medicine Evrysdi in India, which is used for spinal muscular atrophy in adults and children aged two months and older.

Spinal Muscular Atrophy Treatment Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Awareness Regarding Spinal Muscular Atrophy, Its Diagnostics, and Its Treatment
    • 4.2.2 Rise in the Government Initiatives to Improve Healthcare Infrastructure
    • 4.2.3 Increasing R&D Activities to Develop Novel Treatment Regimens for Rare Diseases
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Treatment
    • 4.3.2 Lack of Skilled Professionals for Surgical Procedures and Physiotherapy Regimens
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Type 1
    • 5.1.2 Type 2
    • 5.1.3 Type 3
    • 5.1.4 Type 4
  • 5.2 By Procedure
    • 5.2.1 Gene Replacement Therapy
    • 5.2.2 Drug Therapy
    • 5.2.3 Other Procedures
  • 5.3 By Route of Administration
    • 5.3.1 Oral
    • 5.3.2 Intrathecal
  • 5.4 By Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Novartis International AG
    • 6.1.2 Biogen Inc.
    • 6.1.3 Cytokinetics Inc.
    • 6.1.4 F. Hoffmann - La Roche Ltd
    • 6.1.5 Pfizer Inc.
    • 6.1.6 Isis Pharmaceuticals Inc.
    • 6.1.7 Sanofi Aventis Inc. (GenZyme Corporation)
    • 6.1.8 Avexis Inc.
    • 6.1.9 Catalyst Pharmaceutical
    • 6.1.10 Chugai Pharmaceutical
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Spinal Muscular Atrophy Treatment Industry Segmentation

Spinal muscular atrophy linked to chromosome 5q (SMA) is a recessive, progressive, neuromuscular disorder caused by bi-allelic mutations in the SMN1 gene, resulting in motor neuron degeneration and variable presentation in relation to onset and severity. The spinal muscular atrophy treatment market is segmented by type (type I, type II, type III, and type IV), procedure (gene replacement therapy and drug therapy), route of administration (oral and intrathecal), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments. The report offers the value (in USD million) for the above segments.

By Type Type 1
Type 2
Type 3
Type 4
By Procedure Gene Replacement Therapy
Drug Therapy
Other Procedures
By Route of Administration Oral
Intrathecal
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa GCC
South Africa
Rest of Middle-East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Spinal Muscular Atrophy Treatment Market Research FAQs

What is the current Global Spinal Muscular Atrophy Treatment Market size?

The Global Spinal Muscular Atrophy Treatment Market is projected to register a CAGR of 14.5% during the forecast period (2025-2030)

Who are the key players in Global Spinal Muscular Atrophy Treatment Market?

Biogen, F. Hoffmann - La Roche Ltd, Cytokinetics, Inc.,, Novartis AG and Catalyst Pharmaceutical are the major companies operating in the Global Spinal Muscular Atrophy Treatment Market.

Which is the fastest growing region in Global Spinal Muscular Atrophy Treatment Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Spinal Muscular Atrophy Treatment Market?

In 2025, the North America accounts for the largest market share in Global Spinal Muscular Atrophy Treatment Market.

What years does this Global Spinal Muscular Atrophy Treatment Market cover?

The report covers the Global Spinal Muscular Atrophy Treatment Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Spinal Muscular Atrophy Treatment Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Antiseptic Products Industry Report

Statistics for the 2025 Global Spinal Muscular Atrophy Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Spinal Muscular Atrophy Treatment analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Spinal Muscular Atrophy (SMA) Treatment Market Report Snapshots